Spectrum Pharma (SPPI) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts SPPI Hot Sheet
Financial Fact:
Research and development: 13.29M
Today's EPS Names:
WMK, FACO, SEB, More
Join SI Premium – FREE
Spectrum Pharma (NASDAQ: SPPI) reported Q1 EPS of ($0.36), $0.01 worse than the analyst estimate of ($0.35).
“The progress in our development pipeline speaks to the investigator interest and the commitment of our team during these unprecedented times,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “The PDUFA date for ROLONTIS remains October 24, 2020 and our updated poziotinib strategy is well under way. We continue to drive the business forward and remain focused on achieving our milestones this year.”
For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Latham Group, Inc. (SWIM) Misses Q3 EPS by 5c ; Offers Guidance
- Ternium SA (TX) Misses Q3 EPS by 29c
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
Earnings, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
